Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Glenmark Pharmaceuticals launches Methylene Blue Injection USP in U.S.
Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single Dose Vial.
Glenmark Pharmaceuticals launches Winlevi across key European markets
Glenmark Pharmaceuticals announced that its wholly owned subsidiary Glenmark Specialty S.A (GSSA) has launched Winlevi (clascoterone 10 mg/g cream) across key markets in Europe for the treatment of acne vulgaris.
Glenmark launches Winlevi in key European markets
Glenmark Specialty S.A (GSSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals, today announced the launch of Winlevi (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in adolescents limited to facial application) by the European Commission to Cassiopea S.p.A., a subsidiary of Cosmo N.V. (SIX: COPN) (Cosmo) in October 2025.
Glenmark Pharma Profit Expected To Soar 5x in Two Years, Says Motilal Oswal — Check Target Price
Glenmark Pharma's shares are likely to remain in focus after Motilal Oswal has reiterated its positive stance on the stock.
Stock Alert: KRN Heat, Patanjali Foods, Bharti Airtel, Dixon Tech, Glenmark Pharma, Bharti Hexacom
Securities in F&O Ban:
Glenmark Pharma launches generic Lacosamide injection in US
Glenmark Pharmaceuticals announced that its US subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), in single-dose vials in the United States.
Glenmark Pharmaceuticals Inc. launches Lacosamide Injection USP
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark's Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat2 Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc. [NDA 022254].
After a dull Q4, Glenmark Pharma needs a booster shot to grow
Investors are shifting their focus to core operational execution as the drugmaker looks past one-off licensing gains to drive its FY27 growth.
Stocks to Watch for June 1: IndiGo, Glenmark Pharma, Lupin, NMDC, textile stocks and more
A host of stocks will be in focus on June 1, including IndiGo after its quarterly loss, Glenmark Pharma on strong earnings, Lupin following a US FDA approval, and NMDC after reporting robust revenue growth. Textile stocks may also attract attention after the Centre exempted customs duty on cotton imports until October-end to support the domestic textile industry.
Glenmark Pharma posts robust Q4 performance
Glenmark Pharmaceuticals' consolidated net profit surged more than sixty four times to Rs 301.41 crore in Q4 FY26 from Rs 4.65 core posted in Q4 FY25.
Glenmark Pharma Q4 net profit zooms to ₹301 crore; recommends 250% dividend
Glenmark's Q4FY26 profit surged to ₹301.4 crore, marking a rise of over 6,400% from ₹4.6 crore a year earlier. Shares of Glenmark Pharmaceuticals Ltd ended at ₹2,274.25, down by ₹108.40, or 4.55%, on the BSE today, May 30.
Glenmark Pharma Q4 Result: Net Profit Soars 64 Times, Revenue Rises; Dividend Declared
Revenue from operations jumped 15.8% to 3,771 crore in the quarter under review.